TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04936529: A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma

Sponsor: Memorial Sloan Kettering Cancer Center · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 286 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$9,408,000

Rescue Site Savings

+$6,203,400

Unlock Full NCT04936529 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04936529 Rescue Dossier →